Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
暂无分享,去创建一个
J. Brooks | A. Zoubeidi | R. Nolley | S. Gambhir | C. Kunder | D. Peehl | S. Pitteri | C. Zhang | Tanya Stoyanova | Yun-Sheng Chen | Sahil Kumar | Abel Bermudez | F. Habte | Shiqin Liu | A. Zlitni | Sharon J. Pitteri | A. Ghoochani | E. Hsu | Michelle Shen | Kashyap Koul | M. Rice | Merve Aslan | F. Marques
[1] A. Bardia,et al. Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer , 2019, The New England journal of medicine.
[2] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[3] G. Cheon,et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. , 2019, Endocrine-related cancer.
[4] T. Graeber,et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage , 2018, Science.
[5] Joshua M. Stuart,et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Goldenberg,et al. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target , 2018, Oncotarget.
[7] Marco Novelli,et al. Chromatin organisation and cancer prognosis: a pan-cancer study , 2018, The Lancet. Oncology.
[8] A. Chinnaiyan,et al. Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer , 2017, Clinical Cancer Research.
[9] Michael D. Nyquist,et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.
[10] S. Tavaré,et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer , 2017, Nature Communications.
[11] H. Guan,et al. Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways , 2017, BMC Cancer.
[12] Arnab Ray Chaudhuri,et al. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling , 2017, Nature Reviews Molecular Cell Biology.
[13] H. Beltran,et al. Emerging Variants of Castration-Resistant Prostate Cancer , 2017, Current Oncology Reports.
[14] Henry W. Long,et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.
[15] M. Rubin,et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.
[16] Damian Szklarczyk,et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..
[17] M. Rubin,et al. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. , 2017, Cancer discovery.
[18] S. Andò,et al. v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. , 2016, Cancer research.
[19] Kaitlyn M. Gayvert,et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.
[20] Susan Halabi,et al. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Zeng,et al. Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis , 2016, Scientific Reports.
[22] Joshua M. Stuart,et al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. , 2016, Cancer cell.
[23] Matteo Benelli,et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.
[24] H. Beltran,et al. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer , 2015, Clinical Cancer Research.
[25] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[26] Hsin-Yang Li,et al. Poly(ADP-Ribose) Polymerase 1: Cellular Pluripotency, Reprogramming, and Tumorogenesis , 2015, International journal of molecular sciences.
[27] Edmund A. Rossi,et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) , 2015, Oncotarget.
[28] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[29] M. Gleave,et al. Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts , 2015, Oncotarget.
[30] B. Bonavida,et al. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications , 2015, Genes & cancer.
[31] K. Knudsen,et al. Transcriptional Roles of PARP1 in Cancer , 2014, Molecular Cancer Research.
[32] M. Rubin,et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.
[33] J. Epstein,et al. Small cell carcinoma of the prostate , 2014, Nature Reviews Urology.
[34] A. Ashworth,et al. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency , 2013, Clinical Cancer Research.
[35] J. Siddiqui,et al. Trop-2 promotes prostate cancer metastasis by modulating β(1) integrin functions. , 2013, Cancer research.
[36] Li-Hsin Chen,et al. Poly(ADP-ribose) polymerase 1 regulates nuclear reprogramming and promotes iPSC generation without c-Myc , 2013, The Journal of experimental medicine.
[37] A. Chinnaiyan,et al. Dual roles of PARP-1 promote cancer growth and progression. , 2012, Cancer discovery.
[38] Jiaoti Huang,et al. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. , 2012, Genes & development.
[39] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[40] Michael Peyton,et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.
[41] M. Gerstein,et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.
[42] Mei Jiang,et al. Androgen-responsive gene database: integrated knowledge on androgen-responsive genes. , 2009, Molecular endocrinology.
[43] Bruce Montgomery,et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.
[44] O. Witte,et al. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics , 2008, Proceedings of the National Academy of Sciences.
[45] Ximing J. Yang,et al. Small Cell Carcinoma of the Prostate: An Immunohistochemical Study , 2006, The American journal of surgical pathology.
[46] Daniele Zink,et al. Nuclear structure in cancer cells , 2004, Nature Reviews Cancer.